Dotmatics

Image: 

Credit: Gorodenkoff/Shutterstock

A Cautionary Tale for AI in Small Molecule Drug Discovery

Despite the buzz around artificial intelligence (AI), most industry insiders know that the use of machine learning (ML) in drug discovery is nothing new. For more than a decade, researchers have used computational techniques for many purposes, such as finding hits, modelling drug-protein interactions, and predicting reaction rates.

Dotmatics releases Platform 22.1

Dotmatics, a company that provides scientific informatics software to drive the automation of lab data workflows and accelerate critical R&D discovery, has announced the release of Dotmatics Platform 22.1

Credit: Sergey Nivens/Shutterstock

An AI revolution

Robert Roe finds that the use of AI is driving new areas of research and increasing the competitiveness of early adopters 

Credit: vs148/Shutterstock

BIO-ISAC founded to protect bioeconomy infrastructure

Dotmatics has announced that Charles Fracchia, vice president of data and founder of BioBright, a Dotmatics company, has been appointed to the Bioeconomy Information Sharing and Analysis Center (BIO-ISAC) board of directors and the executive board.

Dotmatics announces licensing agreement for informatics software with Compugen

Dotmatics, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has entered a licensing agreement with Compugen, a clinical-stage drug discovery and development company focused on immuno-oncology. The multi-year agreement will provide Compugen scientists based at the Company’s R&D facility in Israel with a single information management platform.

Pages

Subscribe to RSS - Dotmatics